Summary
The is a first clinical study for Oricell Therapeutics Inc. in the United States to
evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product
(OriCAR-017) in subjects with relapsed/refractory multiple myeloma.
RIGEL Study
Treatment Sites in Georgia
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523